Clinical trials: COVID19 Patients
Covid19, C-reactive Protein
Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.
Although the recent literature is building a remarkable background to answer the many unknowns related to SARS-CoV-2 infection, it is absolutely necessary to finalize every clinical effort to collect data that may be useful, in a…
- Conditions
- Covid19, C-reactive Protein, Procalcitonin, D-dimer
- Trial name
- NCT04873388
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Turin, Italy
COVID-19
Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19
The aim of this project is to introduce way for treatment of patients with severe COVID-19 disease with respiratory complications.
- Trial name
- COVID-19 (NCT04376788)
- Testing
- exchange blood transfusion from normal donor, plasma from convalescent patients with COVID-19, Methylene Blue 5 MG/ML
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Ain Shams University
Covid19, Hypoxemic Respiratory Failure
Endothelial Dysfunction in Covid-19
SARS-CoV-2 targets endothelial cells via the angiotensin-converting enzyme 2 receptor. The specific impact of the resulting endothelial injury is currently unknown but may contribute to the pro-coagulant state classically…
- Trial name
- ENDOCOVID (NCT04830683)
- Where
- Belgium
- Volunteers
- 85 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
COVID
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19.
- Trial name
- OUTCOV (NCT04365582)
- Testing
- Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19
Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection.
- Trial name
- CARECOVID (NCT05172180)
- Testing
- Reamberin, Ringer's solution
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
ARDS, COVID19
Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS
The 2020 pandemic of the coronavirus (SARS-CoV2) has lead to an increase in ARDS cases requiring invasive mechanical ventilation in the ICU (Intensive Care Unit).
- Trial name
- APRV-COVID19 (NCT04386369)
- Testing
- Airway pressure release ventilation
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Central Hospital, Nancy, France
COVID, COVID-19
Detecting SARS-CoV-2 in Tears
Purpose: To determine the presence of SARS-CoV-2 in tears To determine SARS-CoV-2 receptors in tear production system
- Conditions
- COVID, COVID-19, Corona Virus Infection, SARS-CoV-2
- Trial name
- NCT04526769
- Testing
- Tear Collection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Minnesota
Covid19
CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients
The overall objective of the study is to determine the therapeutic effect and tolerance of Camostat mesylate, compared to placebo in adult patients with ambulatory COVID-19 disease, presenting with risk factors of severe…
- Trial name
- CAMOVID (NCT04608266)
- Testing
- Camostat Mesylate
- Where
- 6 sites in France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, COVID-19
COVID-19 Infection in Patients With Hepatocellular Carcinoma
Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic.
- Trial name
- COVID19-CHIEF (NCT04367805)
- Testing
- nasopharyngeal Covid 19 RT-PCR
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
COVID 19, Lymphopenia Due to COVID-19
The Effect of Monocyte Values Accompanied by Lymphopenia on the Prognosis of Patients Diagnosed With COVID-19
Recent studies have shown that lymphopenia with cytokine storm syndrome is frequently found in COVID-19 patients. These features may suggest that the modified immune system plays a key role in determining disease progression.
- Conditions
- COVID 19, Lymphopenia Due to COVID-19, Monocyte
- Trial name
- NCT06968156
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Covid19, ARDS
Risk Factors and Computed Tomography Findings in COVID-19.
In the SARS-CoV2 pandemic, imaging studies proved its diagnostic utility to determine the severity of lung involvement. Computed tomography (CT) is a state-of-the-art study proven to be a highly sensitive diagnostic test…
- Conditions
- Covid19, ARDS, Pneumonia, Viral, Computed Tomography
- Trial name
- NCT04577105
- Testing
- Simple chest tomography
- Where
- Mexico
- Volunteers
- 233 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Angina (Stable), INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain
Long Covid-19 INOCA is an investigator-initiated, prospective, randomized, sham-controlled, single center study. Its objective is to investigate the benefits of tailored medical therapy according to the results of the coronary…
- Conditions
- Angina (Stable), INOCA (Ischemia With Non Obstructive Coronary Artery Disease), Long COVID-19 Syndrome
- Trial name
- NCT07559994
- Testing
- Coronary functional test
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Systemic Lupus Erythematosus, Covid-19
Covid-19 in Lupus Patients
The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.The objective of this…
- Trial name
- NCT04355702
- Where
- France
- Volunteers
- 130 people
- Sponsor
- University Hospital, Montpellier
COVID-19
Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19
This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on D1 to D7) and Azithromycin (500 mg on D1…
- Trial name
- DOXYCOV (NCT04715295)
- Testing
- Doxycycline Tablets, Rivaroxaban 15Mg Tab, Hydroxychloroquine and Azithromycin
- Where
- Cameroon
- Volunteers
- 200 people
- Sponsor
- Yaounde Central Hospital
COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection
The investigators plan to evaluate a strategy of chemoprophylaxis with hydroxyloquine (HCQ) against COVID-19 infection in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with…
- Trial name
- NCT04330495
- Testing
- Hidroxicloroquina, Control group
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Post COVID-19 Syndrome, Rehabilitation
Implementation of Rehabilitation Program for Post COVID-19
Many people who have suffered from the effects of this disease might now be at risk of long-term impairment and disability. The extent of this impairment and disability is yet unknown, but it is clear from early research that…
- Trial name
- NCT04694768
- Testing
- Rehabilitation
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
COVID-19, Hypoxemia
iNOPulse for COVID-19
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
- Conditions
- COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
- Trial name
- NO-COVER (NCT04398290)
- Testing
- Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas
- Where
- United States
- Sponsor
- Roger Alvarez
COVID-19
Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2
Prospective observational single-center study in which the impact of anti-TNF biological treatment on the humoral response after complete vaccination against SARS-COV2 in patients with inflammatory bowel disease is analyzed.
- Trial name
- COVID-19 (NCT05153850)
- Where
- Spain
- Volunteers
- 243 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Corona Virus Infection
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19).
- Trial name
- CORIMUNO-TOC (NCT04331808)
- Testing
- Tocilizumab
- Where
- 8 sites in France
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.